Literature DB >> 23557945

Treatment outcome monitoring of pulmonary tuberculosis cases notified in France in 2009.

D Antoine1, D Che.   

Abstract

The proportion of patients considered to be cured is a key indicator to assess national tuberculosis (TB) control. In France, TB treatment outcome monitoring was implemented in 2007. This article presents national results on treatment outcome among patients with pulmonary TB reported in France in 2009 and explores determinants of potentially unfavourable outcome. Information on treatment outcome was reported for 63% of eligible pulmonary cases of whom 70% had a successful outcome. In a multivariate analysis, potentially unfavourable outcome (17%), compared to treatment success, was significantly associated with being male, born abroad and having lived in France for less than 10 years, being in congregate settings when treatment was initiated, or having a previous history of anti-TB treatment. Enhanced awareness of treatment outcome monitoring is essential to improve the coverage and the quality of information. Earlier diagnosis and improved management of the disease in the elderly may reduce death due to TB. The high proportion of potentially unfavourable outcomes should be further investigated as they may require additional vigilance and/or actions in term of efforts of TB control in some population groups.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557945

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  2 in total

1.  Tuberculosis treatment outcomes of notified cases: trends and determinants of potential unfavourable outcome, France, 2008 to 2014.

Authors:  Jean-Paul Guthmann; Lucie Léon; Delphine Antoine; Daniel Lévy-Bruhl
Journal:  Euro Surveill       Date:  2020-01

Review 2.  Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014.

Authors:  Inge K Holden; Peter H Andersen; Christian Wejse; Troels Lillebaek; Isik S Johansen
Journal:  BMC Health Serv Res       Date:  2020-02-03       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.